Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations.

Verver D, van Klaveren D, van Akkooi ACJ, Rutkowski P, Powell BWEM, Robert C, Testori A, van Leeuwen BL, van der Veldt AAM, Keilholz U, Eggermont AMM, Verhoef C, Grünhagen DJ.

Eur J Cancer. 2018 Jun;96:25-33. doi: 10.1016/j.ejca.2018.02.022. Epub 2018 Apr 13.

PMID:
29660597
2.
3.

From Chemotherapy to Combined Targeted Therapeutics: In Vitro and in Vivo Models to Decipher Intra-tumor Heterogeneity.

Gambara G, Gaebler M, Keilholz U, Regenbrecht CRA, Silvestri A.

Front Pharmacol. 2018 Feb 14;9:77. doi: 10.3389/fphar.2018.00077. eCollection 2018. Review.

4.

Social network, autonomy, and adherence correlates of future time perspective in patients with head and neck cancer.

Baldensperger L, Wiedemann AU, Wessel L, Keilholz U, Knoll N.

Psychooncology. 2018 Jun;27(6):1545-1552. doi: 10.1002/pon.4690. Epub 2018 Mar 24.

PMID:
29490119
5.

Should cT2 esophageal cancer get neoadjuvant treatment before surgery?

Thuss-Patience P, Vecchione L, Keilholz U.

J Thorac Dis. 2017 Sep;9(9):2819-2823. doi: 10.21037/jtd.2017.08.143. No abstract available.

6.

Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells.

Regan JL, Schumacher D, Staudte S, Steffen A, Haybaeck J, Keilholz U, Schweiger C, Golob-Schwarzl N, Mumberg D, Henderson D, Lehrach H, Regenbrecht CRA, Schäfer R, Lange M.

Cell Rep. 2017 Dec 5;21(10):2813-2828. doi: 10.1016/j.celrep.2017.11.025.

7.

Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma.

Lodrini M, Sprüssel A, Astrahantseff K, Tiburtius D, Konschak R, Lode HN, Fischer M, Keilholz U, Eggert A, Deubzer HE.

Oncotarget. 2017 Jul 7;8(49):85234-85251. doi: 10.18632/oncotarget.19076. eCollection 2017 Oct 17.

8.

Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients.

Liu Y, Meucci S, Sheng L, Keilholz U.

Oncotarget. 2017 May 26;8(44):77928-77941. doi: 10.18632/oncotarget.18272. eCollection 2017 Sep 29.

9.

Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.

Klinghammer K, Otto R, Raguse JD, Albers AE, Tinhofer I, Fichtner I, Leser U, Keilholz U, Hoffmann J.

Int J Cancer. 2017 Sep 15;141(6):1215-1221. doi: 10.1002/ijc.30808. Epub 2017 Jun 21.

PMID:
28560858
10.

First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours.

Keilholz U, Rohde L, Mehlitz P, Knoedler M, Schmittel A, Kümmerlen V, Klinghammer K, Treasure P, Lassus M, Steventon G, Machacek M, Utku N.

Eur J Cancer. 2017 Jul;80:14-25. doi: 10.1016/j.ejca.2017.03.032. Epub 2017 May 19.

PMID:
28531881
11.

p16, HPV, and Cetuximab: What Is the Evidence?

Bonner JA, Mesia R, Giralt J, Psyrri A, Keilholz U, Rosenthal DI, Beier F, Schulten J, Vermorken JB.

Oncologist. 2017 Jul;22(7):811-822. doi: 10.1634/theoncologist.2016-0433. Epub 2017 May 18. Review.

PMID:
28526718
12.

Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer.

Reck M, Blais N, Juhasz E, Gorbunova V, Jones CM, Urban L, Orlov S, Barlesi F, Kio E, Keilholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Mittapalli RK, Dunbar M, Ansell P, He L, McKee M, Giranda V, Ramalingam SS.

J Thorac Oncol. 2017 Jul;12(7):1098-1108. doi: 10.1016/j.jtho.2017.04.010. Epub 2017 Apr 29.

13.

Expression of guanylyl cyclase C in tissue samples and the circulation of rectal cancer patients.

Liu Y, Cheng G, Qian J, Ju H, Zhu Y, Stefano M, Keilholz U, Li D.

Oncotarget. 2017 Jun 13;8(24):38841-38849. doi: 10.18632/oncotarget.16406.

14.

[Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma].

Miller K, Bergmann L, Doehn C, Gschwend J, Keilholz U.

Aktuelle Urol. 2017 Feb;48(1):72-78. doi: 10.1055/s-0042-117572. Epub 2017 Apr 12. German.

PMID:
28403496
15.

Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.

Schütte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D, Keil M, Yildiriman R, Jandrasits C, Borodina T, Amstislavskiy V, Worth CL, Schweiger C, Liebs S, Lange M, Warnatz HJ, Butcher LM, Barrett JE, Sultan M, Wierling C, Golob-Schwarzl N, Lax S, Uranitsch S, Becker M, Welte Y, Regan JL, Silvestrov M, Kehler I, Fusi A, Kessler T, Herwig R, Landegren U, Wienke D, Nilsson M, Velasco JA, Garin-Chesa P, Reinhard C, Beck S, Schäfer R, Regenbrecht CR, Henderson D, Lange B, Haybaeck J, Keilholz U, Hoffmann J, Lehrach H, Yaspo ML.

Nat Commun. 2017 Feb 10;8:14262. doi: 10.1038/ncomms14262.

16.

Targeted Therapy of Head and Neck Cancer.

Rieke DT, Klinghammer K, Keilholz U.

Oncol Res Treat. 2016;39(12):780-786. Epub 2016 Nov 22. Review.

17.

Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.

Kidess-Sigal E, Liu HE, Triboulet MM, Che J, Ramani VC, Visser BC, Poultsides GA, Longacre TA, Marziali A, Vysotskaia V, Wiggin M, Heirich K, Hanft V, Keilholz U, Tinhofer I, Norton JA, Lee M, Sollier-Christen E, Jeffrey SS.

Oncotarget. 2016 Dec 20;7(51):85349-85364. doi: 10.18632/oncotarget.13350.

18.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

19.

Systemic Treatment in HPV-Induced Recurrent or Metastatic HNSCC.

Rieke DT, Keilholz U.

Recent Results Cancer Res. 2017;206:149-160. Review.

PMID:
27699536
20.

Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix.

Rieke DT, Ochsenreither S, Klinghammer K, Seiwert TY, Klauschen F, Tinhofer I, Keilholz U.

Oncotarget. 2016 Nov 15;7(46):75379-75393. doi: 10.18632/oncotarget.12211.

21.

appendix 2: Cutaneous melanoma (2): eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Melanoma).

Dummer R, Keilholz U; ESMO Guidelines Committee.

Ann Oncol. 2016 Sep;27(suppl 5):v136-v137. No abstract available.

PMID:
27664250
22.

Mutational load and mutational patterns in relation to age in head and neck cancer.

Meucci S, Keilholz U, Tinhofer I, Ebner OA.

Oncotarget. 2016 Oct 25;7(43):69188-69199. doi: 10.18632/oncotarget.11312.

23.

Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer.

Licitra L, Keilholz U, Tahara M, Lin JC, Chomette P, Ceruse P, Harrington K, Mesia R.

Oral Oncol. 2016 Aug;59:73-79. doi: 10.1016/j.oraloncology.2016.06.002. Review.

24.

The Interdisciplinary Management of Brain Metastases.

Schmieder K, Keilholz U, Combs S.

Dtsch Arztebl Int. 2016 Jun 17;113(24):415-21. doi: 10.3238/arztebl.2016.0415. Review.

25.

Prevalence and associated survival of high-risk HPV-related adenoid cystic carcinoma of the salivary glands.

Qian X, Kaufmann AM, Chen C, Tzamalis G, Hofmann VM, Keilholz U, Hummel M, Albers AE.

Int J Oncol. 2016 Aug;49(2):803-11. doi: 10.3892/ijo.2016.3563. Epub 2016 Jun 3.

PMID:
27279281
26.

Regional hyperthermia combined with chemotherapy in paediatric, adolescent and young adult patients: current and future perspectives.

Seifert G, Budach V, Keilholz U, Wust P, Eggert A, Ghadjar P.

Radiat Oncol. 2016 Apr 30;11:65. doi: 10.1186/s13014-016-0639-1. Review.

27.

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.

Clement PM, Gauler T, Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Cohen EE, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Vermorken JB; LUX-H&N 1 investigators.

Ann Oncol. 2016 Aug;27(8):1585-93. doi: 10.1093/annonc/mdw151. Epub 2016 Apr 15.

28.

Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: An overview.

Frick VO, Rubie C, Keilholz U, Ghadjar P.

World J Gastroenterol. 2016 Jan 14;22(2):833-41. doi: 10.3748/wjg.v22.i2.833. Review.

29.

Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.

Eggermont AM, Suciu S, Rutkowski P, Kruit WH, Punt CJ, Dummer R, Salès F, Keilholz U, de Schaetzen G, Testori A; EORTC Melanoma Group.

Eur J Cancer. 2016 Mar;55:111-21. doi: 10.1016/j.ejca.2015.11.014. Epub 2016 Jan 17.

PMID:
26790144
30.

Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients.

Dielmann A, Letsch A, Nonnenmacher A, Miller K, Keilholz U, Busse A.

Cancer Immunol Immunother. 2016 Feb;65(2):181-92. doi: 10.1007/s00262-015-1786-1. Epub 2016 Jan 11.

PMID:
26753694
31.

Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck.

Licitra L, Mesía R, Keilholz U.

Oral Oncol. 2016 Jan;52:18-23. doi: 10.1016/j.oraloncology.2015.10.020. Epub 2015 Nov 11. Review.

PMID:
26578389
32.

Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.

Arsenic R, Braicu EI, Letsch A, Dietel M, Sehouli J, Keilholz U, Ochsenreither S.

BMC Cancer. 2015 Oct 24;15:784. doi: 10.1186/s12885-015-1824-6.

33.

B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720.

Riechardt AI, Maier AK, Nonnenmacher A, Reichhart N, Keilholz U, Kociok N, Strauss O, Joussen AM, Gundlach E.

Br J Ophthalmol. 2015 Dec;99(12):1739-45. doi: 10.1136/bjophthalmol-2015-306689. Epub 2015 Sep 7.

PMID:
26347528
34.

Next-generation sequencing: hype and hope for development of personalized radiation therapy?

Tinhofer I, Niehr F, Konschak R, Liebs S, Munz M, Stenzinger A, Weichert W, Keilholz U, Budach V.

Radiat Oncol. 2015 Aug 28;10:183. doi: 10.1186/s13014-015-0481-x. Review.

35.

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U; ESMO Guidelines Committee.

Ann Oncol. 2015 Sep;26 Suppl 5:v126-32. doi: 10.1093/annonc/mdv297. No abstract available.

PMID:
26314774
36.

Detection of tumour cells in the bloodstream of patients with uveal melanoma: influence of surgical manipulation on the dissemination of tumour cells in the bloodstream.

Charitoudis G, Schuster R, Joussen AM, Keilholz U, Bechrakis NE.

Br J Ophthalmol. 2016 Apr;100(4):468-72. doi: 10.1136/bjophthalmol-2015-306955. Epub 2015 Aug 17.

PMID:
26283704
37.

Baseline caspase activity predicts progression free survival of temsirolimus-treated head neck cancer patients.

John K, Rösner I, Keilholz U, Gauler T, Bantel H, Grünwald V.

Eur J Cancer. 2015 Aug;51(12):1596-602. doi: 10.1016/j.ejca.2015.05.021. Epub 2015 Jun 2.

PMID:
26048456
38.

A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck.

Machiels JP, Specenier P, Krauß J, Dietz A, Kaminsky MC, Lalami Y, Henke M, Keilholz U, Knecht R, Skartved NJ, Horak ID, Pamperin P, Braun S, Gauler TC.

Cancer Chemother Pharmacol. 2015 Jul;76(1):13-20. doi: 10.1007/s00280-015-2761-4. Epub 2015 May 8.

PMID:
25952795
39.

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators.

Lancet Oncol. 2015 May;16(5):583-94. doi: 10.1016/S1470-2045(15)70124-5. Epub 2015 Apr 16.

PMID:
25892145
40.

Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence.

Tinhofer I, Jöhrens K, Keilholz U, Kaufmann A, Lehmann A, Weichert W, Stenzinger A, Stromberger C, Klinghammer K, Becker ET, Dommerich S, Stölzel K, Hofmann VM, Hildebrandt B, Moser L, Ervens J, Böttcher A, Albers A, Stabenow R, Reinecke A, Budach V, Hoffmeister B, Raguse JD.

Eur J Cancer. 2015 Mar;51(4):514-21. doi: 10.1016/j.ejca.2014.12.018. Epub 2015 Jan 23.

PMID:
25623438
41.

The combinatorial complexity of cancer precision medicine.

Klauschen F, Andreeff M, Keilholz U, Dietel M, Stenzinger A.

Oncoscience. 2014 Jul 23;1(7):504-9. eCollection 2014.

42.

Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics.

Guilhamon P, Butcher LM, Presneau N, Wilson GA, Feber A, Paul DS, Schütte M, Haybaeck J, Keilholz U, Hoffman J, Ross MT, Flanagan AM, Beck S.

Genome Med. 2014 Dec 12;6(12):116. doi: 10.1186/s13073-014-0116-0. eCollection 2014.

43.

TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO).

Grünwald V, Keilholz U, Boehm A, Guntinas-Lichius O, Hennemann B, Schmoll HJ, Ivanyi P, Abbas M, Lehmann U, Koch A, Karch A, Zörner A, Gauler TC.

Ann Oncol. 2015 Mar;26(3):561-7. doi: 10.1093/annonc/mdu571. Epub 2014 Dec 19.

PMID:
25527417
44.

A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.

Klinghammer K, Raguse JD, Plath T, Albers AE, Joehrens K, Zakarneh A, Brzezicha B, Wulf-Goldenberg A, Keilholz U, Hoffmann J, Fichtner I.

Int J Cancer. 2015 Jun 15;136(12):2940-8. doi: 10.1002/ijc.29344. Epub 2014 Nov 26.

45.

Benefits and risks of skin cancer screening.

Breitbart EW, Choudhury K, Anders MP, Volkmer B, Greinert R, Katalinic A, Tacke J, Keilholz U.

Oncol Res Treat. 2014;37 Suppl 3:38-47. doi: 10.1159/000364887. Epub 2014 Aug 29. No abstract available.

46.

Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack.

Henderson D, Ogilvie LA, Hoyle N, Keilholz U, Lange B, Lehrach H; OncoTrack Consortium.

Biotechnol J. 2014 Sep;9(9):1104-14. doi: 10.1002/biot.201400109. Epub 2014 Jul 29. Review.

47.

Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck.

Tinhofer I, Konschak R, Stromberger C, Raguse JD, Dreyer JH, Jöhrens K, Keilholz U, Budach V.

Ann Oncol. 2014 Oct;25(10):2042-7. doi: 10.1093/annonc/mdu271. Epub 2014 Jul 23.

PMID:
25057171
48.

Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance.

Khoja L, Lorigan P, Dive C, Keilholz U, Fusi A.

Ann Oncol. 2015 Jan;26(1):33-9. doi: 10.1093/annonc/mdu207. Epub 2014 Jun 6. Review.

PMID:
24907634
49.

Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway.

Gross A, Niemetz-Rahn A, Nonnenmacher A, Tucholski J, Keilholz U, Fusi A.

Target Oncol. 2015 Mar;10(1):77-84. doi: 10.1007/s11523-014-0318-9. Epub 2014 May 15.

PMID:
24824730
50.

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).

Vermorken JB, Peyrade F, Krauss J, Mesía R, Remenar E, Gauler TC, Keilholz U, Delord JP, Schafhausen P, Erfán J, Brümmendorf TH, Iglesias L, Bethe U, Hicking C, Clement PM.

Ann Oncol. 2014 Mar;25(3):682-8. doi: 10.1093/annonc/mdu003.

Supplemental Content

Loading ...
Support Center